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Abstract: Background: There is some controversy as to whether tirofiban or eptifibatide, two small anti-aggregating 
drugs (AAD), may reduce the incidence of composite ischemic events within one year in patients undergoing   
percutaneous coronary intervention (PCI) in the real clinical world. 
Methods: We compared consecutive patients on oral double AAD (with clopidogrel and aspirin) who underwent PCI 
(n=207) and patients who were on single AAD and received a second AAD, just prior to PCI, and either high-dose  
tirofiban or double-bolus eptifibatide (double AAD plus small molecules group, n=666). The primary end point (incidence 
of composite ischemic events within one year) included death, acute myocardial infarction, unstable angina, stent throm-
bosis or repeat PCI or coronary bypass surgery (related to the target vessel PCI failure) and was modelled by Cox’s re-
gression. 
Results: There were 89 composite ischemic events: 24 (11.6%) in double AAD alone and 65 (9.8%) in double AAD plus 
small molecules groups (log-rank test: p=0.36). Incidences by type of ischemic events were similar between the 2 groups. 
Based on 21 potential covariates fitted simultaneously, adjusted hazard ratios (HR and 95% confidence intervals) showed 
that age (HR 1.03, 1.01-1.06, p=0.01), diabetes (HR 1.68, 1.01-2.79, p=0.05) and intra aortic balloon pump (HR 5.12, 
2.36-11.10, p=0.0001) were significant risk factors whereas thrombolysis by tenecteplase (HR 0.35, 0.13-0.98, p=0.05) 
and having had hypertension or anti-hypertensive treatment (HR 0.58, 0.36-0.93, p=0.03) were significant protectors for 
events. Whether small molecules were present provided a non significant additional benefit as compared to double AAD 
alone (HR 0.83, 0.51-1.36, p=0.46). Pre-PCI CK-MB were not useful to predict events (HR 1.01, 0.99-1.01, p=0.17). 
Conclusions: In clinical world patients undergoing PCI (rescue plus primary <13%) while on double AAD, based on 
clopidogrel plus aspirin, small molecules (tirofiban or eptifibatide) provided no additive long-term protection against the 
occurrence of composite ischemic events whereas thrombolysis by tenecteplase did. 
Keywords: GP IIb/IIIa; tirofiban high-dose; eptifibatide double-bolus; clopidogrel; aspirin; tenecteplase; Thrombolysis; double 
anti-aggregation; ischemic events; PCI. 
INTRODUCTION 
  Although glycoprotein (GP) IIb/IIIa antagonists are   
effective anti aggregating drugs (AAD) in acute coronary 
syndromes (ACS) after percutaneous coronary intervention 
(PCI) [1], the optimal timing to start these agents in unstable 
angina or non-ST elevation myocardial infarction (NSTEMI) 
and the optimal doses and type of agent have not been   
defined [2, 3]. In ST elevation myocardial infarction 
(STEMI) patients, much of the evidence favouring the use of 
GP IIb/IIIa antagonists was obtained in the era before dual 
oral antiplatelet therapy and largely by placebo-controlled 
comparisons [3]. For those patients with STEMI who present  
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to hospitals that do not perform PCI, fibrinolysis is still 
achieved, which was associated with significantly fewer 30-
day ischemic complications if PCI was performed within the 
successive 6 hours [4]. 
  In ACS patients treated by PCI, there are several studies 
assessing the efficacy of eptifibatide versus placebo or ab-
ciximab [5-7] and of abciximab versus high-dose tirofiban 
[8-10]. In STEMI or diabetic patients, meta-analyses were 
performed [11, 12] as the idea that a class effect might be 
present has emerged with accompanying pharmaco-
economic consequences [13-15]. In a single-centre study a 
long-term survival advantage with tirofiban, followed by 
eptifibatide and then abciximab was observed [7]. However, 
among STEMI patients, a substantial similarity between   
tirofiban and abciximab was seen in terms of in-hospital 
safety and 30-day efficacy [10]. On the other hand, the   
incidence of composite ischemic events have been rarely 
investigated [5, 7, 10] and none considered standard therapy 152    The Open Cardiovascular Medicine Journal, 2010, Volume 4  Schiariti et al. 
with double AAD based on clopidogrel and aspirin versus 
small molecules as a group. 
  The Sant’ANna TIrofiban Safety Study (SANTISS: 
www.clinicaltrials.gov Identifier: NCT00566891) compared 
the combination of bleeding and access site complications of 
consecutive, unselected patients undergoing PCI under   
double AAD regimen, in absence or presence of intravenous 
high-dose tirofiban given just prior to PCI (down-stream). 
Between 2004 and 2008, 2205 patients undergoing PCI were 
included in the SANTISS registry [16]. Between 2005 and 
early 2007 a block randomised comparison of high-dose   
tirofiban versus double-bolus eptifibatide [17] was   
performed among patients undergoing PCI while on double 
AAD: the incidence of ischemic events within one year was 
the primary end-point, which is reported here. Thus patients 
who underwent PCI on double AAD with clopidogrel and 
aspirin during the randomised phase of SANTISS are   
compared to patients treated with the additive use of 
GPIIb/IIIa antagonistic small molecules tirofiban or eptifi-
batide, considered as a group. Pre-PCI levels of creatine-
kinase myocardial band (CK-MB) were measured since: a) 
small molecules may affect them, b) this may impact on 
long-term ischemic event incidence [18], and c) there is a 
close relation between peri-procedural myocardial infarct 
and one year mortality [19]. 
MATERIALS AND METHODS 
  All patients at Sant’Anna Hospital, Catanzaro, who un-
derwent elective, primary or rescue PCI were eligible to be 
enrolled in SANTISS [16]. Patients referred from another 
hospital with ongoing tirofiban or eptifibatide treatment were 
excluded from this study. A block randomisation scheme 
was selected to fit the ongoing progress of SANTISS and the 
power calculated based on the following: a) a 3 to 6% abso-
lute one year survival difference between treatments during a 
3-year accrual time; b) a 3 to 4 ratio between tirofiban- and 
eptifibatide-enrolled patients; c) a maximum of 2% patients 
lost to follow-up; and d) a log-rank test power analysis with 
alpha equal to 5% and power greater than 80%. Accordingly, 
675 consecutive patients were block-randomized: there were 
75 blocks of 4 and 75 blocks of 5 patients, each having one 
patient randomized to eptifibatide and the remaining to ti-
rofiban. 
  Patients who were on oral single antiplatelet regimen 
(ASA or clopidogrel) received a down-stream open-label 
GPIIb/IIIa small molecule (tirofiban or eptifibatide) and a 
second oral antiplatelet agent was added immediately before 
PCI. When the first AAD was clopidogrel, the second agent 
was ASA (at the loading dose of 160-325 mg orally and then 
80-125 mg orally indefinitely). If the first antiplatelet agent 
was ASA, we gave clopidogrel as the second agent (at the 
loading dose of 300 mg orally and then 75 mg/d for at least 3 
months). Patients who already were on oral double AAD 
regimen (ASA at 80-125 mg/d plus clopidogrel 75 mg/d) 
were considered as a separate group. Patients who were on 
oral ASA plus ticlopidine or who had ticlopidine as the first 
AAD were excluded. A few patients in whom a second oral 
antiplatelet drug could not be used were also excluded [16]. 
  GPIIb/IIIa small molecules were given as follows: a) 
high-dose tirofiban [16]: 25 g/Kg bolus followed by 0.15 
g/Kg/min 18-hour infusion; b) double-bolus eptifibatide 
[17]: 180 g/Kg bolus, followed by 2 g/Kg/min 18-hour 
infusion, and 10 min after a second 180 g/Kg bolus. 
  For the purpose of the present analysis the time frame of 
data collection was from PCI to one year after. The primary 
end-point was the combination of ischemic events: cardiac 
death, acute myocardial infarction, unstable angina, acute 
stent thrombosis or the need for repeat PCI or coronary by-
pass surgery (related to the target vessel PCI failure), all as-
sociated with a date but with identical rank order. When 
more than 1 event occurred only the first one was consid-
ered. An external reviewer (PEP), unaware of treatment as-
signment, coded all events. Subgroups of patients referred to 
perform a rescue-PCI within 6 hours after thrombolysis were 
included. 
  All patients underwent pre- and post-procedural standard 
electrocardiograms (ECG). CK-MB was routinely measured 
at admission in hospital as well as 6 and 12 hours after the 
procedure and before discharge. Q-wave myocardial infarc-
tion was diagnosed when new Q waves appeared at least in 
two leads with an increase in CK-MB at least twice upper 
the normal limit (core laboratory upper limit: 15 U/l) was 
observed. Non-Q-wave myocardial infarction was diagnosed 
when an increase in CK-MB at least threefold upper the 
normal limit was observed. 
  Interventions were performed by 6- or 7-F guiding cathe-
ter using the femoral approach. Operators were free to 
choose the more adequate catheter curves, guidewires and 
stents whose type (drug-eluting versus bare-metal), length, 
diameter, and number were coded but are not considered for 
the purpose of the present analysis. A bolus of heparin (70 
UI/kg) was given before starting the procedure in order to 
maintain an activated clotting time (ACT) of 250 s; further 
doses of heparin were given to adjust ACT when necessary. 
  Data obtained from a dedicated data form for SANTISS 
by means of a purposely compiled (by DC) software facili-
tated the automatic transfer from records on paper to an Ex-
cel file which was analysed by BMDP statistical package 
after transformation into a machine readable file. Summary 
statistics of continuous variables were expressed as mean 
value ± SD whereas discrete variables were given only as 
proportions. T-test was used to assess inter-group differ-
ences. Log-rank test was used to test the univariate inter-
group significance in the incidence (Kaplan-Meier curves) of 
composite events during 365 days of follow-up. Moreover, 
the presence (coded 1) or absence (coded 0) of composite 
events was modelled by using Cox’s proportional hazards 
model, an exponential model of survival (Y) prediction 
whereby it is easy to obtain the probability of an event func-
tion (1-Y) given by: 1-Y = S(0) exponent of coefficient A1 
(x1-X1) * exponent of coefficient An (xn-Xn), which is cal-
culated based on the cumulative proportional hazard (S(0)) 
and on the coefficients of covariates (A1 to An), which stay 
in the model solution. All covariates were in at step zero 
(forced method) in order to compute their individual relative 
contribution. Further details are given elsewhere [20]. NCSS 
software version 2007 (released August 14, 2007 by J 
Hintze, Kaysville, Utah; see www.ncss.com) was used and 
Wald’s t values and probability level, along with hazard ra-
tios (HR) and ±95% confidence intervals (CI) were com-Tirofiban vs. Eptifibatide at Long-Term After PCI  The Open Cardiovascular Medicine Journal, 2010, Volume 4     153 
puted [20-22]. A value of p<0.05 was considered statistically 
significant. 
RESULTS 
  Of the 885 consecutive patients who underwent elective 
PCI at Sant’Anna hospital or were sent for primary or rescue 
PCI between February 2005 and March 2007, while SAN-
TISS was ongoing [16], 525 were block-randomized (3.5:1) 
to tirofiban and 150 to eptifibatide. There were 12 (1.4%) 
patients who were lost to follow-up: 6 (1.1%) in the tirofiban 
and 3 (2%) in the eptifibatide group and 3 (1.4%) in the dou-
ble AAD alone group. There were therefore 666 patients in 
the double AAD plus GPIIa/IIIb small molecules group and 
207 patients in the double AAD alone group. 
  There were 89 composite ischemic events within one 
year, including death, acute myocardial infarction, unstable 
angina, stent thrombosis or repeat PCI or coronary bypass 
surgery (primary end-point on the present study): 24 (11.6%) 
in double AAD alone and 65 (9.8%) in double AAD plus 
small molecules groups (log-rank test: p=0.36, Fig. 1). There 
was no significant difference in the proportions of specific 
ischemic events within one year between double AAD pa-
tients without or with small molecules: major events (death 
or acute myocardial infarction) were seen respectively in 10 
(4.8%) and 17 (2.6%) patients, minor events were respec-
tively 8 (3.9%) and 20 (3.0%) for unstable angina, 2 (1.0%) 
and 7 (0.6%) for stent thrombosis and 4 (1.9%) and 21 
(3.1%) for repeat PCI or coronary bypass surgery. The haz-
ard rate presentation was superposable between the groups 
(Fig. 2). There were only 9 of 873 (1.0%) patients who pre-
sented with multiple events and 8 were seen in the tirofiban 
group. 
 
 
 
 
 
 
 
 
 
 
 
 
Fig. (1). Kaplan-Meier curves show non significant (by log-rank 
test) difference between the cumulative incidences of composite 
ischemic events in double anti-aggregating drug (AAD) alone 
group versus double AAD plus glycoprotein (GP) IIb/IIIa (eptifi-
batide or tirofiban) group. The primary end point was the composite 
of cardiac death, acute myocardial infarction, angina, acute stent 
thrombosis or the need for repeat percutaneous coronary interven-
tion or coronary bypass surgery, all with identical rank order. When 
more than one event occurred only the first one was considered. 
 Table  1 shows the multivariate prediction of composite 
ischemic events within one year based on 21 potential co-
variates fitted simultaneously by Cox’s model. Adjusted 
hazard ratios showed that age (HR 1.03, 95%CI 1.01-1.06, 
p=0.01), diabetes (HR 1.68, 95%CI 1.01-2.79, p=0.05) and 
intra aortic balloon pump (HR 5.12, 95%CI 2.36-11.10, 
p=0.0001) were significant risk factors whereas thrombolysis 
by tenecteplase (HR 0.35, 95%CI 0.13-0.98, p=0.05) and 
having had hypertension or anti-hypertensive treatment (HR 
0.58, 95%CI 0.36-0.93, p=0.03) were significant protectors 
for events. Whether small molecules were present provided a 
non significant additional benefit as compared to double 
AAD alone (HR 0.83, 95%CI 0.51-1.36, p=0.46). Pre-PCI 
CK-MB were not useful to predict events (HR 1.01, 95%CI 
0.99-1.01, p=0.17). The remaining covariates had a slightly 
contributor role but did not reach the statistical level of   
significance. In particular there was no contribution of the 
variable coding for the number of treated coronary vessels. 
 
 
 
 
 
 
 
 
 
Fig. (2). Comparison between double anti-aggregating drug (AAD) 
alone group versus double AAD plus glycoprotein (GP) IIb/IIIa 
(eptifibatide or tirofiban) group show similarly continuous decreas-
ing hazard rate, from immediately after percutaneous coronary in-
tervention to one year afterwards. 
DISCUSSION 
  We showed that one year composite ischemic events   
after PCI in real clinical world patients in whom primary or 
rescue interventions were less than 13%, were not signifi-
cantly different whether GP IIb/IIIa small molecules were 
added or not in the context of double AAD with standard 
(300 mg) clopidogrel and aspirin. Among these patients 
where pre-PCI CK-MB were not useful to predict events 
thrombolysis by tenecteplase was a significant protective 
factor. 
  As this evidence was obtained with an extended observa-
tion period and a robust predictive model was fitted with all 
potential contributors simultaneously assessed, it is impor-
tant to see these data in the spotlight of the class-action con-
cepts of small anti-aggregating molecules versus abciximab 
[7-12, 14, 15], high-dose (600 mg or more) clopidogrel [23] 
and other drugs such as prasugrel [24, 25] or bivaluridin 
[26], a series of agents that may actually be considered as 
optimal treatments in these patients [3]. For all these effec-
tiveness-related comparisons it will be essential to obtain 
pharmaco-econometric data [13] and/or interaction results 
with peculiar stenting types [10]. It might be also warranted 
to consider these results when adopting policy and recom-
mendations existing for patients undergoing PCI [1-3] since 
recent evidence in patients with STEMI plays against differ-
ing too much PCI after thrombolysis [4]. 
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  One may argue that the no significant modification of 
long-term outcome seen here was not the consequence of 
protective failure due to GP IIb/IIIa small molecules but 
rather to similar efficacy of the two underlying regimens of 
double AAD, both with clopidogrel and aspirin. GP IIb/IIIa 
small molecules were given in our study so that their anti-
aggregating action would be present during the window 
phase necessary for 300 mg clopidogrel loading dose fully 
developed its action. On the other hand, those patients who 
were on clopidogrel (75 mg/d) were put on double AAD by 
receiving aspirin loading doses (160-325 mg). When patients 
presented with double AAD with clopidogrel and aspirin 
they were not given GPIIb/IIIa small molecules. However, it 
is important to understand that these latter patients were on 
clopidogrel 75 mg/d and aspirin 80-125 mg/d. There are no 
comparative studies where the long-term efficacy of these 
pharmacodynamically different double AAD regimens have 
been assessed and therefore we are unable to dissociate, be-
tween our two groups, whether this affected and/or how 
much our results. Neither could we exclude that higher than 
300 mg loading doses of clopidogrel (with or without GP 
IIb/IIIa small molecules) could be even more effective and a 
long-term difference would be observed as compared to our 
double AAD alone patients. Clearly ad hoc studies are 
needed. 
Table 1.  Multivariable Prediction of Outcome Within One Year Based on 21 Potential Covariates Fitted Simultaneously in 873 
PCI Patients 
Cox’s Regression  Risk  Probability  95% CI 
Independent  Coefficient 
(B) 
Standard 
Error of B 
Ratio 
Exp(B) 
Mean  Wald 
Z-Value 
Level 
(p)  Lower          Upper 
Demographic and Clinical 
Age 0.032076  0.012133  1.0326  62.7064  2.6437  0.0082  1.0083  1.0574 
Sex 0.144729  0.281673  1.1557  0.1873  0.5138  0.6074  0.6654  2.0073 
Unstable angina  0.337566  0.430571  1.4015  0.3329  0.7840  0.4330  0.6027  3.2592 
Stable angina  0.076764  0.520495  1.0798  0.1237  0.1475  0.8828  0.3893  2.9949 
Previous AMI  -0.039625  0.407752  0.9611  0.4439  -0.0972  0.9226  0.4322  2.1373 
Shock 0.613903  0.568932  1.8476  0.0150  1.0790  0.2806  0.6058  5.6350 
Risk factors 
Family history  0.246289  0.240704  1.2793  0.3341  1.0232  0.3062  0.7981  2.0505 
Hypertension -0.544924  0.243305  0.5799  0.6775  -2.2397  0.0251  0.3599  0.9342 
Smoking habit  0.192062  0.254528  1.2117  0.4012  0.7546  0.4505  0.7358  1.9956 
Dyslipidemia -0.130751  0.237286  0.8774  0.6613  -0.5510  0.5816  0.5511  1.3970 
Chronic renal failure  0.502925  0.469929  1.6536  0.0347  1.0702  0.2845  0.6583  4.1536 
Diabetes 0.519194  0.259368  1.6807  0.3017  2.0018  0.0453  1.0109  2.7942 
Diabetes insulin 
        -dependent  0.062199  0.380990  1.0642  0.0786  0.1633  0.8703  0.5043  2.2455 
Procedural 
Pre-PCI CK-MB  0.001469  0.001070  1.0015  39.7827  1.3733  0.1697  0.9994  1.0036 
Primary PCI  0.891688  0.819129  2.4392  0.0116  1.0886  0.2763  0.4898  12.1478 
Rescue PCI  0.097730  0.637583  1.1027  0.1168  0.1533  0.8782  0.3160  3.8473 
Thrombolysis by TEC  -1.041799  0.521827  0.3528  0.1329  -1.9964  0.0459  0.1269  0.9811 
IABP 1.633311  0.394628  5.1208  0.0659  4.1389  0.0000  2.3628  11.0980 
Number  vessels  treated -0.078796  0.290966  0.9242  1.1457  -0.2708  0.7865 0.5225  1.6347 
ICUS -0.097346  0.402393  0.9072  0.0867  -0.2419  0.8088  0.4123  1.9964 
Outcome for ischemic events within one year 
GPIIb/IIIa vs absence  -0.184206 0.252018 0.8318  0.7653  -0.7309  0.4648  0.5076 1.3631 
AMI = acute myocardial infarction; IABP= intra aortic balloon pump; ICUS = intra coronary ultra sound; PCI= percutaneous coronary intervention; TEC= tenecteplase; CI: confi-
dence intervals of relative risk. Note that the model is forced, meaning that all 21 covariates stay in at step zero. Note that the coding of the Grouping variable GPIIb/IIIa vs absence 
was Double anti-aggregating drug (AAD) treatment only=0; Double AAD and GPIIb/IIIa=1. Thus, in this study where the proportion of Double AAD and GPIIb/IIIa patients was 
83%, the multivariate risk of composite ischemic events within one year was not significantly (p=0.4648) lower (Wald t=-0.73, 95%CI 0.5076-1.3631) than in those receiving Dou-
ble AAD only. Tirofiban vs. Eptifibatide at Long-Term After PCI  The Open Cardiovascular Medicine Journal, 2010, Volume 4     155 
 Lotrionte  et al. recently presented a systematic review 
and meta-analysis of the optimal clopidogrel loading dose in 
patients scheduled for catheterization and/or PCI in the Lit-
erature as of December 2006 [23]. Overall, a high loading 
dose had an efficacy, also among randomized trials alone, 
much higher than the standard loading dose: cardiac death or 
nonfatal myocardial infarction were prevented (odds ratio 
0.54, 95% CI 0.32-0.90, p=0.02), without any statistically 
significant increase in major or minor bleedings (p=0.55 and 
p=0.98, respectively). Interestingly, meta-regression dis-
closed a significant interaction between event rate and the 
benefits of high loading doses (p=0.005), suggesting that the 
greater the underlying risk, the greater the favourable impact 
of a high loading dose. Therefore efficacy seemed dose-
dependent in spite of a dose-independent safety profile. Nev-
ertheless, results over one months of these regimens remain 
unknown. 
  There is only one single centre investigation to have 
evaluated the long-term mortality after administration of 
abciximab, eptifibatide, and tirofiban during PCI [7]. How-
ever, the bolus-only strategy was investigated, based on the 
idea that it might be similar in efficacy, safer, and more cost-
effective compared to a bolus plus infusion of GP IIb/IIIa 
inhibitors. The long-term mortality was not significantly 
different in the tirofiban group compared to the abciximab 
group (p=0.33) or the eptifibatide group (p=0.20) [7]. We 
provide support to these data, although it is important to 
point out that the perfusion strategy we adopted was   
different as were the definitions of the primary end-point and 
the observation period. 
  The relations of elevated CK-MB to clinical outcomes 
after PCI in patients enrolled in Integrilin to Minimize Plate-
let Aggregation and Coronary Thrombosis-II (IMPACT-II) 
trial on eptifibatide was investigated among patients under-
going elective, scheduled PCI for any indication [18].   
Parallel analyses investigated CK (n=3535) and CK-MB 
(n=2341) levels after PCI (within 4 to 20 h). Elevated CK-
MB was associated with an increased risk of death, re-
infarction, or emergency revascularization at 30 days, and of 
death, re-infarction, or surgical revascularization at 6 
months. The degree of risk correlated with the rise in CK or 
CK-MB, even for patients with successful procedures not 
complicated by abrupt closure [18]. In the present study, pre-
PCI CK-MB was unrelated to outcome. 
  A very recent meta-analysis [12] of 6 randomized trials 
on STEMI patients involving 2197 patients showed that   
abciximab did not reduce 30-day
 mortality (2.2% vs. 2.0%, p 
= 0.66) or re-infarction (1.2% vs.
 1.2%, p = 0.88), nor was 
there any difference in major bleeding
 complications (1.3% 
vs. 1.9%, p = 0.27).
 Thus, among STEMI patients undergo-
ing primary PCI,
  similar results between abciximab and 
small molecules in terms
  of angiographic, electrocardio-
graphic, and clinical outcome [12] may dictate the selection 
of the less expensive among these agents [13], especially   
if a class-effect is present, as quite recently hypothesized   
[14, 15]. 
  More recently, in patients with ACS with scheduled PCI, 
it was shown that with prasugrel, careful titration might be 
necessary to obtain a safety profile comparable to an   
efficacy-equivalent dose of clopidogrel [25]. On the other 
hand, in STEMI patients undergoing primary PCI with 
bivalirudin or unfractionated heparin plus a GP IIb/IIIa   
inhibitor, a 600 mg clopidogrel loading dose was an inde-
pendent predictor of lower rate of 30-day major adverse car-
diac events (HR 0.72, 95% CI 0.53-0.98), p=0.04). Finally, 
there is evidence that statins exert multiple beneficial effects 
on patients undergoing PCI [27]. A limitation of our study is 
that whether statins were given at baseline was not recorded. 
  In conclusion, patients undergoing PCI (the great   
majority by elective procedure) while on double antiplatelet 
therapy (with clopidogrel and aspirin) have an incidence of 
composite ischemic events within one year which is not   
significantly different when they also receive GP IIb/IIIa 
small molecules. It seems that these effects are not related to 
CK-MB changes. The protective long-term role of throm-
bolysis was observed as was the higher risk due to intra aor-
tic balloon pump, diabetes and older age. Having had hyper-
tension or anti-hypertensive treatment was a significant pro-
tector for events, an observation which fits with epidemi-
ologic data where the paradox of treated hypertension as a 
protective factor is frequently seen. 
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